Back to Results

CASI Pharmaceuticals Inc (CASIF)

CASI Pharmaceuticals Inc is a Beijing-based biopharmaceutical company whose common stock trades on OTC Markets under the symbol CASI.F. Founded in 1991, the company develops and commercializes therapeutics and pharmaceutical products in China, the United States, and other international markets. Its marketed product portfolio includes EVOMELA, an intravenous formulation of melphalan used in conditioning before stem cell transplantation and as palliative treatment for multiple myeloma, as well as Thiotepa, a chemotherapeutic agent with several indications, including use before certain allogeneic hematopoietic stem cell transplants. CASI’s hematology and oncology pipeline includes CNCT19, BI-1206, CB-5339, and CID-103. The company also has licensing agreements with Juventas Cell Therapy, BioInvent International, Black Belt Therapeutics, Cleave Therapeutics, and Acrotech Biopharma related to EVOMELA development and commercialization.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-CASI.F
$0.20
46.7% Upside
Undervalued
$4 2,863.0% Upside
—
Bargain
Weak
—
—
—
0.0%
August 14, 2026
-0.1x
-0.1x
0.2x
2.775 M
23.55 M
90.8%
47.3%
-113.9
—
43.2%
Valuation • Fair Value

CASI Pharmaceuticals Inc (OTC-CASI.F) Fair Value by Valuation Model

Compare the primary fair value estimate for CASI Pharmaceuticals Inc (OTC-CASI.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.20

Estimated upside of 46.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.20

Comparable-company valuation reference.

Analyst Price Target

$4 2,863.0% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for CASI Pharmaceuticals Inc (OTC-CASI.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for CASI Pharmaceuticals Inc (OTC-CASI.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

20.712 M

Current operating scale indicator.

Revenue Forecast

20.712 M

Forward revenue estimate.

EBITDA

-41.589 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review CASI Pharmaceuticals Inc (OTC-CASI.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CASI Pharmaceuticals Inc (OTC-CASI.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-8.57

No elevated caution signal from this screen.

Altman Z-Score

-113.9

Lower score that deserves closer risk review.

FCF / Net Income

43.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CASI Pharmaceuticals Inc (OTC-CASI.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CASI Pharmaceuticals Inc (OTC-CASI.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 14, 2026

Days to Earnings

24

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for CASI Pharmaceuticals Inc (OTC-CASI.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CASI Pharmaceuticals Inc (OTC-CASI.F) Stock Forecast & Technical Outlook

Review CASI Pharmaceuticals Inc (OTC-CASI.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CASI Pharmaceuticals Inc (OTC-CASI.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, CASI Pharmaceuticals Inc (OTC-CASI.F) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

CASI Pharmaceuticals Inc (OTC-CASI.F) Stock FAQ

Quick answers about CASI Pharmaceuticals Inc (OTC-CASI.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.20
Estimated upside 46.7%
Valuation Rating
Undervalued
Estimated upside of 46.7%
Analyst Target
$4 2,863.0% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for CASI Pharmaceuticals Inc (OTC-CASI.F) is $0.20. This implies an estimated upside of 46.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 46.7% versus the current market price.

The available analyst price target for CASI Pharmaceuticals Inc (OTC-CASI.F) is $4 2,863.0% Upside.

The current financial health read for CASI Pharmaceuticals Inc (OTC-CASI.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CASI Pharmaceuticals Inc (OTC-CASI.F) is August 14, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for CASI Pharmaceuticals Inc (OTC-CASI.F) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for CASI Pharmaceuticals Inc is 2.775 M.

The current enterprise value listed for CASI Pharmaceuticals Inc is 23.55 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CASI Pharmaceuticals Inc is OTC-CASI.F, and the stock is listed on OTC Markets.

CASI Pharmaceuticals Inc (OTC-CASI.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for CASI Pharmaceuticals Inc is 90.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CASI Pharmaceuticals Inc is 47.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)